WO1990002808A2 - Fermentation of genetically engineered yeast in the presence of a polyalkylene compound - Google Patents

Fermentation of genetically engineered yeast in the presence of a polyalkylene compound Download PDF

Info

Publication number
WO1990002808A2
WO1990002808A2 PCT/GB1989/001046 GB8901046W WO9002808A2 WO 1990002808 A2 WO1990002808 A2 WO 1990002808A2 GB 8901046 W GB8901046 W GB 8901046W WO 9002808 A2 WO9002808 A2 WO 9002808A2
Authority
WO
WIPO (PCT)
Prior art keywords
albumin
process according
added
fermentation
compound
Prior art date
Application number
PCT/GB1989/001046
Other languages
French (fr)
Other versions
WO1990002808A3 (en
Inventor
Peter Maurice Clarke
Stephen Hugh Collins
David John Mead
Original Assignee
Delta Biotechnology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10643175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1990002808(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Delta Biotechnology Limited filed Critical Delta Biotechnology Limited
Priority to DE68921063T priority Critical patent/DE68921063T2/en
Priority to EP89910461A priority patent/EP0386222B1/en
Priority to KR1019900700909A priority patent/KR900702001A/en
Publication of WO1990002808A2 publication Critical patent/WO1990002808A2/en
Publication of WO1990002808A3 publication Critical patent/WO1990002808A3/en
Priority to DK107490A priority patent/DK107490A/en
Priority to FI902259A priority patent/FI96040C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound

Definitions

  • This invention provides improved fermentation methods and, in particular, a method of increasing the quantity of human serum albumin (hereinafter "albumin”) produced by fermentation of an rDNA-containing micro ⁇ organism which is capable of secreting albumin into the medium.
  • albumin human serum albumin
  • Albumin is a major component of blood plasma and can be used as a plasma or serum substitute to treat burns, haemorrhagic shock and other conditions. Methods have been described whereby albumin can be produced by fermentation of microorganisms into which the gene for albumin has been introduced by recombinant DNA technology (GB-A-2147903) .
  • such organisms are so constructed as to secrete albumin into the surrounding culture fluid because intracellular albumin, in common with many other heterologous proteins, is produced in an inactive, insoluble form from which the native protein can be obtained only with great difficulty (see, for example, M. Latta et . al. 1987 Bio/Technology 5 . 1309-1314) .
  • intracellular albumin in common with many other heterologous proteins, is produced in an inactive, insoluble form from which the native protein can be obtained only with great difficulty (see, for example, M. Latta et . al. 1987 Bio/Technology 5 . 1309-1314) .
  • In order to maximize the productivity of the manufacturing process it is desirable to grow the microorganisms in a highly agitated aerated fermenter to achieve high concentrations of cells and product. Unfortunately these conditions leave the secreted protein exposed to physical, chemical and enzymatic degradation in the intracellular medium such that the quantity of albumin produced in the fermenter is much less than might have been expected from the performance of
  • Any suitable polyalkylene polymer or copolymer with another compound may be used, for example polyethylene glycol; polypropylene glycol; polysorbate 80; copolymers of ethylene oxide and propylene oxide; and copolymers of ethylene oxide and/or propylene oxide with other compounds, such as fatty acids, fatty alcohols, sugars and polyols, for example sugar alcohols (e.g. sorbitol), ethylene glycol, pentaerythritol and glycerol .
  • polyethylene glycol polypropylene glycol
  • polysorbate 80 copolymers of ethylene oxide and propylene oxide
  • copolymers of ethylene oxide and/or propylene oxide with other compounds such as fatty acids, fatty alcohols, sugars and polyols, for example sugar alcohols (e.g. sorbitol), ethylene glycol, pentaerythritol and glycerol .
  • Polyoxypropylene polymers have the general formula HO-(CH 2 -CH(CH 3 )-0)n-H.
  • Suitable polyoxyethylene polyoxypropylene copolymers include those which can be represented as X-(0-(CH 2 -CH(CH 3 )-0) a -(CH 2 -CH 2 0)» -H)L where X is a polyol containing 1 hydroxyl groups , 1 is 2- 6, m is 10-30 and n is 0-10.
  • Another suitable series of compounds uses polyethylene glycol as the polyol , having two available hydroxyl groups, each substitutable by a -0 (CH 2 -CH( CHa )-0) n -H group where each n is the same or different.
  • polyoxyalkylene compounds All of the compounds and classes of compounds referred to above are referred to herein as "polyoxyalkylene compounds” . These compounds are usually, but not always, antifoam compounds. If such a compound does not have antifoam properties, then the phrase "in excess of the amount required to suppress undesirable levels of foam” means in an amount greater than zero. Suitable compounds include those available under the trade designations "Darastil” (for example “Darastil 8231”) (Grace Dearborn Ltd, Widnes , Cheshire, U.K.) and Breox FMT30 (Water Management Chemicals Ltd, Kidderminster, Worcs, U.K. )
  • High cell densities in microbial fermentations are commonly achieved by fed-batch culture. Under these conditions the fermenter is part-full at the start of the process and contains only a small fraction of the carbon substrate. As the fermentation proceeds a concentrated solution of the carbon substrate, and possibly other nutrients, is gradually added. Antifoams are a common process aid in such a process, foam control being achieved by a sensor situated near the top of the fermenter which actuates the addition of antifoam when foam is detected. Since the fermenter is only partially filled at the start, little or no antifoam is added in the early stages of the fermentation and it is only towards the end of the process, as the vessel fills up, that a head of foam is likely to reach and actuate the sensor.
  • Typical usage rates are 0.02-0.2g/l fermentation broth.
  • the stabilising agent is added from the start (or at an early stage) of the fermentation.
  • the reagent may be added either in a single dose at or near the start of fermentation or it may be added gradually or intermittently in a series of aliquots through the process. In this way it is possible to maintain approximate proportionality between cell biomass or albumin, on the one hand, and reagent on the other.
  • One or more suitable stabiliser compounds may be used. Usage rates for this process are such as to yield a concentration of stabiliser (or of total stabilisers, if more than one is used) of between O. ⁇ and lOg/l (preferably l-5g/l) .
  • concentration of stabiliser or of total stabilisers, if more than one is used
  • the process is not restricted to this type of fermentation.
  • Use of these reagents at these concentrations is also applicable to the production of albumin in simple batch culture or in continuous culture. In the latter case the reagent can be added continuously or intermittently to maintain a concentration in the desired range of 0.5-10g/l (preferably 1- ⁇ g/l).
  • stabilisers of the invention has been found to be beneficial with relatively low-yielding strains of yeast. With certain strains of yeast, which give higher yields of albumin, the beneficial effect may be less noticeable if the fermentation protocol is such as to produce high cell densities, but is still detectable if lower cell densities are produced.
  • the albumin may be any naturally-occurring or modified form of albumin, including fragments thereof, provided that the compound retains at least one functional characteristic of HSA, for example its oncotic or ligand-binding properties or its utility in laboratory media.
  • the albumin may be the fragment disclosed in EP-A-322 094.
  • Secretion may be mediated by any suitable signal sequence, for example the pre-HSA sequence or the yeast alpha-factor signal sequence.
  • the microorganism may be any organism (including animal or plant cell cultures) which secretes albumin into the fermentation medium, such as suitable strains of bacteria (for example Bacillus or Streptomyces spp. ) or yeasts (such as Saccharomyces cerevisiae or Kluyveromyces lactis ) .
  • suitable strains of bacteria for example Bacillus or Streptomyces spp.
  • yeasts such as Saccharomyces cerevisiae or Kluyveromyces lactis
  • Albumin-secreting yeasts and their fermentation to produce albumin are disclosed in EP-A-322 094 and EP-A-201 239. Examples
  • Example 1 Stabilisation of albumin in fermentation medium.
  • a laboratory fermenter was filled to half its nominal working volume with an initial "batch" medium containing 50ml/l of a salts mixture (containing 114g/l KH 2 P0 4 , 12g/l MgS0 4 , 3.0g/l CaCl 2 .6H 2 0, 2.0g/l Na 2 EDTA; lOml/1 of a trace elements solution containing 3g/l ZnSO..7H 2 0, lOg/1 FeS0 4 .7H 2 0, 3.2g/l MnSO..4H 2 0, ' 79mg/l CuS0 4 .5H 2 0, 1.5g/l H 3 B0 3 , 0.2g/l KI , 0.5g/l Na 2 Mo0 4 .2H 2 0, 0.56g/l CoCl 2 .6H 2 0, 75ml/l H 3 P0 4 ; 20g/l sucrose; 50ml/l of a vitamins mixture containing 1.6g/l Ca pantothenate ,
  • DOT dissolved oxygen tension
  • PPG 2000 was added in response to a foam sensor. None was added until over 50% of the feed solution had been added. The final level of addition was 0.2g/l. Biomass concentration at the end of the fermentation was 93g/l. About 90% of the albumin initially present was degraded within 24h of the start of the feed.
  • PPG 2000 added solely in response to foam sensor. Nil at fermentation start, increasing to O.lg/1 after 10% of the feed was added, then rising to a final level of 0.2g/l during the last 50% of the feed. The final biomass was 84g/l, and the albumin level was noted on an arbitrary scale to be 1.0 unit.
  • Example 2B
  • Polyricinate added to 1.5g/l at start of ermentation, increasing further to 2.2g/l after 35% of feed added with further increases to maintain a level of 2.5g/l when feed was nearly complete. A further addition after the feed was over raised the final level to 3.5g/l. Final biomass 83g/l, albumin level 3.81 units.
  • PPG 2000 added to an initial value of lg/1 with further additions after 50% and 80% of the feed had been added to maintain this concentration.
  • Final biomass 86g/l, albumin concentration 4.2 units.
  • Example 2 A series of the fed-batch fermentations were set up according to the procedure of Example 2 except that a different strain of S. cerevisiae (but still containing the plasmid for secreted albumin) was used. Antifoams were added according to the protocol of Example 2C with the following results. Antifoam Biomass Albumin Concentration (g/1) (arbitrary units)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

The yield of secreted human serum albumin in a fermentation of genetically engineered yeast can be increased if a polyoxyalkylene compound is added, for example polypropylene glycol or polyoxypropylene/polyoxyethylene copolymers. Some of these compounds are routinely used in fermentation as antifoam compounds, but at lower levels.

Description

FERMENTATION OF GENETICALLY ENGINEERED YEAST IN THE PRESENCE OF A POLYALKYLENE COMPOUND
This invention provides improved fermentation methods and, in particular, a method of increasing the quantity of human serum albumin (hereinafter "albumin") produced by fermentation of an rDNA-containing micro¬ organism which is capable of secreting albumin into the medium.
Albumin is a major component of blood plasma and can be used as a plasma or serum substitute to treat burns, haemorrhagic shock and other conditions. Methods have been described whereby albumin can be produced by fermentation of microorganisms into which the gene for albumin has been introduced by recombinant DNA technology (GB-A-2147903) .
It is preferable that such organisms are so constructed as to secrete albumin into the surrounding culture fluid because intracellular albumin, in common with many other heterologous proteins, is produced in an inactive, insoluble form from which the native protein can be obtained only with great difficulty (see, for example, M. Latta et. al. 1987 Bio/Technology 5. 1309-1314) . In order to maximize the productivity of the manufacturing process it is desirable to grow the microorganisms in a highly agitated aerated fermenter to achieve high concentrations of cells and product. Unfortunately these conditions leave the secreted protein exposed to physical, chemical and enzymatic degradation in the intracellular medium such that the quantity of albumin produced in the fermenter is much less than might have been expected from the performance of the organisms in less intensive conditions.
We have found that the addition of certain chemical reagents is effective in raising the concentration of secreted albumin especially in minimal media (i.e. growth media which do not contain complex organic sources of nitrogen). In particular the addition of certain antifoam agents to levels much greater than those required for normal foam control has this stabilising effect. Effective reagents include polypropylene glycol (average molecular weight 2,000) and "polyricinate" (a condensate of castor oil fatty acids and ethylene oxide produced by Croda Chemicals ) .
Any suitable polyalkylene polymer or copolymer with another compound may be used, for example polyethylene glycol; polypropylene glycol; polysorbate 80; copolymers of ethylene oxide and propylene oxide; and copolymers of ethylene oxide and/or propylene oxide with other compounds, such as fatty acids, fatty alcohols, sugars and polyols, for example sugar alcohols (e.g. sorbitol), ethylene glycol, pentaerythritol and glycerol .
Polyoxypropylene polymers have the general formula HO-(CH2 -CH(CH3 )-0)n-H. Suitable polyoxyethylene polyoxypropylene copolymers include those which can be represented as X-(0-(CH2 -CH(CH3 )-0)a-(CH2 -CH20)» -H)L where X is a polyol containing 1 hydroxyl groups , 1 is 2- 6, m is 10-30 and n is 0-10. Another suitable series of compounds uses polyethylene glycol as the polyol , having two available hydroxyl groups, each substitutable by a -0 (CH2 -CH( CHa )-0)n-H group where each n is the same or different.
All of the compounds and classes of compounds referred to above are referred to herein as "polyoxyalkylene compounds" . These compounds are usually, but not always, antifoam compounds. If such a compound does not have antifoam properties, then the phrase "in excess of the amount required to suppress undesirable levels of foam" means in an amount greater than zero. Suitable compounds include those available under the trade designations "Darastil" (for example "Darastil 8231") (Grace Dearborn Ltd, Widnes , Cheshire, U.K.) and Breox FMT30 (Water Management Chemicals Ltd, Kidderminster, Worcs, U.K. )
High cell densities in microbial fermentations are commonly achieved by fed-batch culture. Under these conditions the fermenter is part-full at the start of the process and contains only a small fraction of the carbon substrate. As the fermentation proceeds a concentrated solution of the carbon substrate, and possibly other nutrients, is gradually added. Antifoams are a common process aid in such a process, foam control being achieved by a sensor situated near the top of the fermenter which actuates the addition of antifoam when foam is detected. Since the fermenter is only partially filled at the start, little or no antifoam is added in the early stages of the fermentation and it is only towards the end of the process, as the vessel fills up, that a head of foam is likely to reach and actuate the sensor. Typical usage rates are 0.02-0.2g/l fermentation broth. In contrast, in the process here described, the stabilising agent is added from the start (or at an early stage) of the fermentation. The reagent may be added either in a single dose at or near the start of fermentation or it may be added gradually or intermittently in a series of aliquots through the process. In this way it is possible to maintain approximate proportionality between cell biomass or albumin, on the one hand, and reagent on the other.
One or more suitable stabiliser compounds may be used. Usage rates for this process are such as to yield a concentration of stabiliser (or of total stabilisers, if more than one is used) of between O.δ and lOg/l (preferably l-5g/l) . Although the use of fed-batch culture is particularly suitable for the production of high cell densities for heterologous protein production, the process is not restricted to this type of fermentation. Use of these reagents at these concentrations is also applicable to the production of albumin in simple batch culture or in continuous culture. In the latter case the reagent can be added continuously or intermittently to maintain a concentration in the desired range of 0.5-10g/l (preferably 1-δg/l).
The use of the stabilisers of the invention has been found to be beneficial with relatively low-yielding strains of yeast. With certain strains of yeast, which give higher yields of albumin, the beneficial effect may be less noticeable if the fermentation protocol is such as to produce high cell densities, but is still detectable if lower cell densities are produced.
The albumin may be any naturally-occurring or modified form of albumin, including fragments thereof, provided that the compound retains at least one functional characteristic of HSA, for example its oncotic or ligand-binding properties or its utility in laboratory media. In particular, the albumin may be the fragment disclosed in EP-A-322 094. Secretion may be mediated by any suitable signal sequence, for example the pre-HSA sequence or the yeast alpha-factor signal sequence.
The microorganism may be any organism (including animal or plant cell cultures) which secretes albumin into the fermentation medium, such as suitable strains of bacteria (for example Bacillus or Streptomyces spp. ) or yeasts (such as Saccharomyces cerevisiae or Kluyveromyces lactis ) . Albumin-secreting yeasts and their fermentation to produce albumin are disclosed in EP-A-322 094 and EP-A-201 239. Examples
Example 1. Stabilisation of albumin in fermentation medium.
A laboratory fermenter was filled to half its nominal working volume with an initial "batch" medium containing 50ml/l of a salts mixture (containing 114g/l KH2P04 , 12g/l MgS04 , 3.0g/l CaCl2.6H20, 2.0g/l Na2 EDTA; lOml/1 of a trace elements solution containing 3g/l ZnSO..7H20, lOg/1 FeS04.7H20, 3.2g/l MnSO..4H20, ' 79mg/l CuS04.5H20, 1.5g/l H3B03 , 0.2g/l KI , 0.5g/l Na2Mo04.2H20, 0.56g/l CoCl2.6H20, 75ml/l H3P04 ; 20g/l sucrose; 50ml/l of a vitamins mixture containing 1.6g/l Ca pantothenate , 1.2g/l nicotinic acid, 12.8g/l inositol, 0.32g/l thiamine HCl, 0.8g/l pyridoxine HCl and 8mg/l biotin. An equal volume of "feed" medium containing lOOml/l of the salts mixture, 20ml/l of trace elements solution 500g/l sucrose and lOOml/l vitamin solution was held in a separate reservoir connected to the fermenter by a metering pump.
500mg/l albumin was added to the fermenter which was inoculated with Saccharomyces cerevisiae . pH was maintained at 5.7 +. 0.2 by automatic addition of ammonia or sulphuric acid, the temperature was kept at 30° C and the stirrer speed was adjusted to give a dissolved oxygen tension (DOT) of > 20% air saturation at 1 v/v/min air flow rate. When the initial substrate had been consumed, the metering pump was turned on, maintaining a growth rate of approximately 0.15h_1. The pump rate was increased to maintain this growth rate until the stirrer speed reached its maximum value at which point it was not possible to increase the pump rate any further without causing the DOT to fall below 15% air saturation which was the minimum value permitted to occur. PPG 2000 was added in response to a foam sensor. None was added until over 50% of the feed solution had been added. The final level of addition was 0.2g/l. Biomass concentration at the end of the fermentation was 93g/l. About 90% of the albumin initially present was degraded within 24h of the start of the feed.
In a subsequent experiment under otherwise identical conditions PPG was added at the start of fermentation to a level of lg/1. The progress of the fermentation was very similar, reaching a final dry weight of 94g/l, but in this case albumin degradation was subsequently reduced so that at the end of the fermentation about 60% of the albumin originally present was undegraded. Example 2. Increasing Concentration of Secreted Albumin
A series of experiments were set up using the fed batch protocol described above with the modification that in this case the pump rate was increased automatically using a computer control system which also monitored respiratory quotient (RQ) so that the feed rate was reduced if RQ exceeded 1.2. This procedure avoids possible yield loss by the "Crabtree" affect. In all cases fermenters were inoculated with Saccharomyces cerevisiae containing a plasmid which codes for secreted albumin production. The following protocols were used for antifoam addition with the following results.
Example 2A (comparative example)
PPG 2000 added solely in response to foam sensor. Nil at fermentation start, increasing to O.lg/1 after 10% of the feed was added, then rising to a final level of 0.2g/l during the last 50% of the feed. The final biomass was 84g/l, and the albumin level was noted on an arbitrary scale to be 1.0 unit. Example 2B
Polyricinate added to 1.5g/l at start of ermentation, increasing further to 2.2g/l after 35% of feed added with further increases to maintain a level of 2.5g/l when feed was nearly complete. A further addition after the feed was over raised the final level to 3.5g/l. Final biomass 83g/l, albumin level 3.81 units.
Example 2C
PPG 2000 added to an initial value of lg/1 with further additions after 50% and 80% of the feed had been added to maintain this concentration. Final biomass 86g/l, albumin concentration 4.2 units.
Example 3. Increasing Concentration of Secreted Albumin (second case)
A series of the fed-batch fermentations were set up according to the procedure of Example 2 except that a different strain of S. cerevisiae (but still containing the plasmid for secreted albumin) was used. Antifoams were added according to the protocol of Example 2C with the following results. Antifoam Biomass Albumin Concentration (g/1) (arbitrary units)
Arachis oil 95.4 1.0
Crill 1 86.8 0.8
Breox FMT30 81.8 3.2
Darastil 8231 81.6 2.5
It is apparent that the polyalkene oxide derived antifoams (Darastil 8231 and Breox FMT30) give higher albumin yields than the others.

Claims

1. A process for preparing human serum albumin by fermenting an albumin-secreting microorganism in a suitable medium such that albumin is secreted into the medium, characterised in that a polyoxyalkylene compound is added to the medium in excess of the amount required to suppress undesirable levels of foam.
2. A process according to Claim 1 wherein the polyoxy- alkylene compound is so added as to give an average level of more than 0.2g/l.
3. A process according to Claim 2 wherein the polyoxy¬ alkylene compound is so added as to give an average level of 0.5 to lOg/1.
4. A process according to Claim 3 wherein the polyalkylene compound is so added as to give an average level of 1.0 to 5.0g/l.
5. A process according to any other of the previous claims wherein the polyoxyalkylene compound is an antifoam compound.
6. A process according to any one of the preceding claims wherein the polyoxyalkylene compound is a polypropylene glycol; a condensate of castor oil fatty acids and ethylene oxide; a copolymer of propylene oxide and ethylene oxide with a polyol; or a copolymer of propylene oxide and polythylene glycol.
7. A process according to any one of the preceding claims wherein the microorganism is a yeast.
8. A process according to Claim 7 wherein the yeast is Saccharomyces cerevisiae .
9. A process according to any one of the preceding claims wherein the medium is a minimal medium.
10. Albumin produced by a process according to any one of the preceding claims.
PCT/GB1989/001046 1988-09-07 1989-09-06 Fermentation of genetically engineered yeast in the presence of a polyalkylene compound WO1990002808A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE68921063T DE68921063T2 (en) 1988-09-07 1989-09-06 Process for the preparation of human serum albumin by fermentation of a genetically modified microorganism in the presence of a polyalkylene.
EP89910461A EP0386222B1 (en) 1988-09-07 1989-09-06 Process for preparing human serum albumine by fermenting a genetically engineered microorganism in the presence of a polyalkylene compound
KR1019900700909A KR900702001A (en) 1988-09-07 1989-09-06 zymotechnics
DK107490A DK107490A (en) 1988-09-07 1990-05-01 METHOD OF PREPARING HUMAN SERUM ALBUM
FI902259A FI96040C (en) 1988-09-07 1990-05-04 Fermentation process for the preparation of human serum albumin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888820951A GB8820951D0 (en) 1988-09-07 1988-09-07 Fermentation method
GB8820951.5 1988-09-07

Publications (2)

Publication Number Publication Date
WO1990002808A2 true WO1990002808A2 (en) 1990-03-22
WO1990002808A3 WO1990002808A3 (en) 1990-04-19

Family

ID=10643175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1989/001046 WO1990002808A2 (en) 1988-09-07 1989-09-06 Fermentation of genetically engineered yeast in the presence of a polyalkylene compound

Country Status (14)

Country Link
EP (1) EP0386222B1 (en)
JP (1) JP2996405B2 (en)
KR (1) KR900702001A (en)
AT (1) ATE118249T1 (en)
AU (1) AU618413B2 (en)
CA (1) CA1336416C (en)
DE (1) DE68921063T2 (en)
DK (1) DK107490A (en)
FI (1) FI96040C (en)
GB (1) GB8820951D0 (en)
HU (1) HU207350B (en)
IE (1) IE61268B1 (en)
WO (1) WO1990002808A2 (en)
ZA (1) ZA896847B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404317A2 (en) * 1989-06-22 1990-12-27 Petrolite Corporation Use of ethoxylated propoxylated alcohols to prevent or reduce foam in fermentation broths
EP0504823A2 (en) * 1991-03-20 1992-09-23 The Green Cross Corporation Method for producing human serum albumin
EP1004673A1 (en) * 1997-04-03 2000-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Process for producing foreign proteins

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0822893B2 (en) * 1995-04-27 2005-04-13 Sucher & Holzer Bauplanungs- und Handelsgesellschaft mbh Worm press
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CN101511868B (en) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 Exendin fusion proteins
JP7050528B2 (en) * 2017-03-01 2022-04-08 三洋化成工業株式会社 Production method of useful substances

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073646A2 (en) * 1981-08-28 1983-03-09 Genentech, Inc. Construction of DNA sequences and their use for microbial production of proteins, in particular human serum albumin
EP0262516A2 (en) * 1986-09-29 1988-04-06 Miles Inc. Genetic transformation of lactic acid bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2417410C2 (en) * 1973-04-11 1983-02-24 Cincinnati Milacron-Heald Corp., 01606 Worcester, Mass. Grinding machine for processing hollow cylindrical workpieces with a cross-section deviating from the circular shape
DE2917535C2 (en) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Insulin solutions resistant to denaturation
GB8613388D0 (en) * 1986-06-03 1986-07-09 Delta Biotechnology Ltd Induction of galactose regulated gene expression in yeast

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073646A2 (en) * 1981-08-28 1983-03-09 Genentech, Inc. Construction of DNA sequences and their use for microbial production of proteins, in particular human serum albumin
EP0262516A2 (en) * 1986-09-29 1988-04-06 Miles Inc. Genetic transformation of lactic acid bacteria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, File 5, Biosis, Biosis number 82023603, KI W K et al: "Development of yeast saccharomyces - cere-visiae vector system for eukaryotic gene cloning optimum condition for intact yeast cell transformation and plasmid stability in the transofrmants", Korean J appl Microbiol bioeng 14(2), 1986, 125-132. *
Gene, Vol. 25, 1983 Robert J. Klebe et al: "A general method for polyethylene-glycol-induced genetec transformation of bacteria and yeast. ", see page 333 - page 341. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404317A2 (en) * 1989-06-22 1990-12-27 Petrolite Corporation Use of ethoxylated propoxylated alcohols to prevent or reduce foam in fermentation broths
EP0404317A3 (en) * 1989-06-22 1991-10-02 Petrolite Corporation Use of ethoxylated propoxylated alcohols to prevent or reduce foam in fermentation broths
EP0504823A2 (en) * 1991-03-20 1992-09-23 The Green Cross Corporation Method for producing human serum albumin
EP0504823A3 (en) * 1991-03-20 1993-04-07 The Green Cross Corporation Method for producing human serum albumin
EP1004673A1 (en) * 1997-04-03 2000-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Process for producing foreign proteins
EP1004673A4 (en) * 1997-04-03 2003-01-15 Mitsubishi Pharma Corp Process for producing foreign proteins

Also Published As

Publication number Publication date
ZA896847B (en) 1990-07-25
WO1990002808A3 (en) 1990-04-19
FI96040C (en) 1996-04-25
DK107490D0 (en) 1990-05-01
ATE118249T1 (en) 1995-02-15
KR900702001A (en) 1990-12-05
IE61268B1 (en) 1994-10-19
DE68921063T2 (en) 1995-07-06
DE68921063D1 (en) 1995-03-23
AU618413B2 (en) 1991-12-19
DK107490A (en) 1990-05-01
IE892864L (en) 1990-03-07
HUT56398A (en) 1991-08-28
FI902259A0 (en) 1990-05-04
CA1336416C (en) 1995-07-25
FI96040B (en) 1996-01-15
HU207350B (en) 1993-03-29
AU4310789A (en) 1990-04-02
GB8820951D0 (en) 1988-10-05
EP0386222B1 (en) 1995-02-08
JPH03500969A (en) 1991-03-07
EP0386222A1 (en) 1990-09-12
HU895572D0 (en) 1991-07-29
JP2996405B2 (en) 1999-12-27

Similar Documents

Publication Publication Date Title
Porro et al. Replacement of a metabolic pathway for large-scale production of lactic acid from engineered yeasts
KR100572426B1 (en) Protein production process
Chang et al. High density cell culture by membrane-based cell recycle
US5260202A (en) Fermentation method
CN107937360B (en) High-density fermentation method of glucose oxidase in pichia pastoris
Grootjen et al. Cofermentation of glucose and xylose with immobilized Pichia stipitis and Saccharomyces cerevisiae
EP2407544A1 (en) Production method for 1,3-propanediol using recombinant microbial strain having glycerol oxidation metabolic pathway blocked
CA1336416C (en) Production of human serum albumin by fermentation
CN100368524C (en) High density fermentation method for GS115/PFK-K5
Tsuge et al. Development of a novel method for feeding a mixture of L-lactic acid and acetic acid in fed-batch culture of Ralstonia eutropha for poly-D-3-hydroxybutyrate production
CN112608963A (en) Method for culturing pichia pastoris engineering bacteria through semi-continuous fermentation
CN101250507B (en) Batch supplying fermentation technique for producing acetonic acid oxidase high-effectively by using recombinant bacillus coli
CN101654666B (en) Biocatalyst for production of d-lactic acid
CN100434509C (en) Method of continuous culture of anaerobic bacterium
EP0136802B1 (en) Industrial-scale process for the production of polyols by fermentation of sugars (1111111)
Hwang et al. Continuous production of acrylamide by Brevibacterium sp. immobilized in a dual hollow fiber bioreactor
CA1206433A (en) Production of biological products using resting cells
CN101255440B (en) Recombinant polymorphism hansenula as well as special recombinant expression vectors and uses thereof
CN102517223A (en) High-density fermentation process and equipment for methanol type pichia pastoris
CN202415541U (en) Special equipment being applicable to high-concentration culture of methanol pichia methanolica
Grøn et al. Production of proteinase A by Saccharomyces cerevesiae in a cell-recycling fermentation system: experiments and computer simulations
KR102202694B1 (en) Novel methylotrophic bacteria variant with overexpression of ftfL gene and method for producing PHB using the same
CN1130463C (en) Fermentation process by expressing recombined protein in bacillus
Chalmers et al. A simple membrane reactor to obtain high cell density and plasmid encoded protein production from Escherichia coli
CN116286408A (en) Yeast fermentation medium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI GB HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989910461

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI GB HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 902259

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1989910461

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989910461

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 902259

Country of ref document: FI